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Phosphodiesterase-5 (PDE5) is the target for sildenafil, vard-
enafil, and tadalafil, which are drugs for treatment of erectile dys-
function and pulmonary hypertension.We report here the crystal
structures of a fully active catalytic domain of unligandedPDE5A1
and its complexes with sildenafil or icarisid II. These structures
together with the PDE5A1-isobutyl-1-methylxanthine complex
show that the H-loop (residues 660–683) at the active site of
PDE5A1 has four different conformations and migrates 7–35 Å
upon inhibitor binding. In addition, the conformation of sildenafil
reported herein differs significantly from those in the previous
structures of chimerically hybridized or almost inactive PDE5.
Mutagenesis and kinetic analyses confirm that the H-loop is par-
ticularly important for substrate recognition and that invariant
Gly659, which immediately precedes theH-loop, is critical for opti-
mal substrate affinity and catalytic activity.
Cyclic nucleotide phosphodiesterases (PDEs)3 are key
enzymes controlling cellular concentrations of secondmessen-
gers cAMP and cGMP by hydrolyzing them to 5-AMP and
5-GMP, respectively. The human genome encodes 21 PDE
genes that are categorized into 11 families (1–9). Alternative
mRNA splicing of the PDE genes produces over 60 PDE iso-
forms that distribute in various cellular compartments and con-
trol physiological processes. PDE molecules contain a con-
served catalytic domain and variable regulatory regions.
However, each PDE family possesses a characteristic pattern of
substrate specificity and inhibitor selectivity (6).
Inhibitors of PDEs have been widely studied as therapeu-
tics as follows: cardiotonics, vasodilators, smooth muscle
relaxants, antidepressants, antithrombotics, antiasthmatics,
and agents for improving cognitive functions such as learn-
ing andmemory (10–17). Some of the most successful exam-
ples of these drugs are the PDE5 inhibitors sildenafil
(Viagra), vardenafil (Levitra), and tadalafil (Cialis) that
have been used for treatment of male erectile dysfunction (15).
Sildenafil has also recently been approved (Revatio) for treat-
ment of pulmonary hypertension (18). However, reported side
effects of these medications such as headache and visual dis-
turbance suggest a need for further study of themolecular basis
of the selectivity of PDE5 inhibitors (19).
Two co-crystal structures of the catalytic domain of PDE5with
sildenafil showed differences in the conformation of the inhibitor
bound to the catalytic site (20–22).However, it remains unknown
whether these conformations are biologically relevant because the
PDE5 enzymeused in the studies is either almost inactive (20) or a
chimeric hybridof thePDE5catalytic domainwith replacementof
a PDE4 segment (the H-loop) (21, 22). In addition, the crystal
structure of the catalytic domain of PDE5A1 in complex with the
nonselective PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX)
showed that the conformation of the H-loop at the active site is
different from that in PDE4 (23) and in other published PDE5
structures (20–22, 24). We report here the structure of the cata-
lytic domain of human PDE5A1 in the unliganded state, as well as
the structures of the protein in complex with inhibitors sildenafil
and icarisid II (Fig. 1). These structures, together with that of
PDE5A1-IBMX, reveal four different conformations of the
H-loop, which is juxtaposed to the catalytic pocket of the enzyme.
In addition, comparison of this PDE5-sildenafil structure with the
previously published structures shows significantly different con-
formations of the methylpiperazine portion of sildenafil. These
unique features of the PDE5 catalytic domain and the sildenafil
configuration are key considerations for understanding the action
of sildenafil and for development of PDE5 inhibitors.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification of Catalytic Domain
PDE5A1—The cDNA of the catalytic domain of human
PDE5A1 was generated by site-directed mutagenesis of the
bovine PDE5A cDNA (23). The coding regions for amino
acids 535–860 of PDE5A1 were amplified by PCR and sub-
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cloned into the expression vector pET15b. The resultant
plasmid pET-PDE5A1 was transferred into Escherichia coli
strain BL21 (Codonplus) for overexpression. The E. coli cell
carrying pET-PDE5A1 was grown in LB medium at 37 °C to
an A600  0.7, and 0.1 mM isopropyl -D-thiogalactopyrano-
side was then added for further growth at 15 °C overnight.
Recombinant PDE5A1 was purified by the columns of nick-
el-nitrilotriacetic acid (Qiagen), Q-Sepharose, and
Sephacryl S300 (Amersham Biosciences). A typical purifica-
tion yielded over 10 mg of PDE5A1 with a purity of 95%
from a 2-liter cell culture.
The mutant proteins with deletion of residues 663–678 and
661–681 were produced by the standard protocol of site-di-
rected mutagenesis. For the deletion mutant proteins, four gly-
cine residues were inserted as the spacer to minimize the dis-
turbance on the three-dimensional structure. Overexpression
andpurification of themutant proteins used the sameprotocols
as for the nonmutated protein.
Expression and Purification of Full-length hPDE5A1—Hu-
man cDNAcoding for full-length PDE5A1was cloned into pCR
2.1-TOPO vector (Invitrogen) and then ligated into the bacu-
lovirus expression vector pAcHLT-A (Pharmingen). The
resulting plasmid pAcA-PDE5 (Met1–Asn875) was used to
make point mutations (G659A, V660Q, N661A, N662A,
Y664A, H678A, and S679A) with theQuikChange site-directed
mutagenesis kit (Stratagene). Wild type and mutant constructs
of hPDE5A1 were expressed in Sf9 cells. Sf9 cells were cotrans-
fected with BaculoGold linear baculovirus DNA (Pharmingen)
and one of the pAcA-hPDE5A1 plasmids. The cotransfection
supernatant was collected at 5 days post-infection, amplified
three times in Sf9 cells, and then used directly as virus stock
without additional purification. Sf9 cells grown at 27 °C in com-
plete Grace’s insect medium with 10% fetal bovine serum and
10 g/ml gentamicin (Sigma) were typically infected with 100
l of viral stock and then harvested at 92 h post-infection. Pro-
tein yields were 2.7 mg/liter infected cell media and were
largely soluble.
The Sf9 cell pellet (2  107 cells) was resuspended in ice-
cold lysis buffer (20mMTris-HCl, pH 8, 100mMNaCl) contain-
ing protease inhibitor mixture, homogenized, and centrifuged.
The supernatant was loaded onto a nickel-nitrilotriacetic acid-
agarose (Qiagen) column equilibrated with lysis buffer. The
column was washed with lysis buffer containing a stepwise gra-
dient of 0.8–20 mM imidazole and eluted with 100 mM imidaz-
ole. Eluted PDE5A1 protein was dialyzed versus 2000 volumes
of ice-cold 10 mM potassium phosphate, pH 6.8, 25 mM -mer-
captoethanol, and 150mMNaCl.All recombinant PDE5A1pro-
teins exhibited a purity of 98% as determined by SDS-PAGE.
Enzymatic Assay—Enzymatic activity of the isolated catalytic
domains of wild type PDE5A1 and its deletion mutants was
assayed by using [3H]cGMP as substrate in a reaction mixture
of 20 mM Tris-HCl, pH 7.8, 1.5 mM dithiothreitol, 10 mM
MgCl2, [3H]cGMP (40,000 cpm/assay) at 24 °C for 15 min (25).
The reaction was terminated by addition of 0.2 M ZnSO4 and
Ba(OH)2. Radioactivity of unreacted [3H]cGMP in the superna-
tant was measured by a liquid scintillation counter. The turn-
over rate was measured at nine concentrations of cGMP and
controlled at hydrolysis of 15–40% substrate. Each measure-
ment was repeated three times. For measurement of IC50 val-
ues, 10 concentrations of inhibitors were used at a substrate
concentration that was one-tenth of the Km value and an
enzyme concentration that hydrolyzed 50% of substrate.
To assay the activity of full-length hPDE5A1, the reaction
mixture contained 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.3
mg/ml bovine serum albumin, 0.05–250 M cGMP, and
[3H]cGMP (100,000–150,000 cpm/assay) and one of the
PDE5A1 proteins (26). Incubation time was 10 min at 30 °C. In
all studies, less than 10% of total [3H]cGMP was hydrolyzed
during the reaction. All values determined represent three
measurements. The Km and kcat values for cGMP were deter-
mined by nonlinear regression analysis of data using Prism
GraphPad software.
Crystallization and Data Collection—All crystals of
PDE5A1-(535–860) were grown by vapor diffusion. The pro-
FIGURE 1. Chemical structures of PDE5 inhibitors. The letters R1–R3 label the main groups in sildenafil and icarisid II. In sildenafil, R1 represents the pyrazo-
lopyrimidinone group; R2 is ethoxyphenyl, and R3 is methylpiperazine. In icarisid II, R1 represents the methoxyphenyl group; R2 is oxychromone, and R3 is
rhamnose.
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tein drop was prepared by mixing 2 l of protein with 2 l of
well buffer. The unliganded PDE5A1 crystal was grown at room
temperature against well buffer of 0.2 MMgSO4, 0.1 MTris base,
pH 8.5, 12% PEG 3350, and 2% ethanol. The PDE5A1-sildenafil
complexwas prepared bymixing 1mM sildenafil with 15mg/ml
PDE5A1 at 4 °C overnight and crystallized against a well buffer
of 1.0 M sodium citrate, 2.5% ethanol, 0.1 M HEPES, pH 7.5, at
4 °C. The PDE5A1-icarisid II complex was prepared by mixing
2 mM icarisid II with 15 mg/ml protein at 4 °C overnight, and
crystallized against a well buffer of 0.1 M HEPES, pH 7.5, 12%
PEG3350 at room temperature.
The unliganded PDE5A1-(535–860) was crystallized in the
space group P3121with cell dimensions of a b 74.7 and c
130.7 Å. The PDE5A1-sildenafil crystal had the space group
P6222 with cell dimensions of a  b  164.6 and c  193.1 Å.
The PDE5A1-icarisid II crystal had the space group P6122 with
cell dimensions of a b 110.7 and c 106.2Å. BeamlineX25
at Brookhaven National Laboratory was used for collection of
diffraction data of the unliganded PDE5A1 and X29 for
PDE5A1-sildenafil and PDE5A1-icarisid II (Table 1). All data
were processed by the program HKL (27).
Structure Determination—The structure of the unligan-
ded PDE5A1 was solved by rigid body refinement of the
PDE5A1 catalytic domain in PDE5A1-IBMX. The structures
of PDE5A1 in complex with sildenafil and icarisid II were
solved by the molecular replacement program AMoRe (28),
using the PDE5A1-IBMX structure without the H-loop and
IBMX as the initial model. The rotation and translation
searches for the crystal of PDE5A1-icarisid II yielded a correla-
tion coefficient of 0.74 and R-factor of 0.31 for 3054 reflections
between 4 and 8 Å resolution. The rotation and translation
searches for PDE5A1-sildenafil yielded a correlation coefficient
of 0.22 andR-factor of 0.52 for 11,612 reflections between 4 and
8 Å resolution for the first molecule, and of 0.39 and 0.41 after
the second molecule was added. The electron density map was
improved by the density modification package of CCP4 (29).
The atomicmodel was rebuilt by programO (30) and refined by
program CNS (Table 1) (31).
RESULTS
Multiple Conformations of the H-loop of PDE5—The crystal-
lographic asymmetric units contain one molecule of the cata-
lytic domain in the structures of the unliganded PDE5A1 and
the icarisid II complex but three molecules in PDE5A1-silde-
nafil structure. The electron density maps showed that the
entire catalytic domain in the PDE5A1-icarisid II structure and
molecule A in the PDE5A1-sildenafil structure were traceable.
However, residues 668–676 of molecules B and C in the
PDE5A1-sildenafil crystal and residues 793–807 in the unli-
ganded PDE5A1 lacked electron density and were disordered.
The Ramachandran plots showed that the backbone conforma-
tions of 90–94% residues in the three structures were located in
the most favored regions, and no residues were located in the
energetically disallowed regions.
The structures of the unliganded PDE5A1 catalytic domain
(residues 535–860) and its complexes with sildenafil or icarisid
II are composed of 14 common -helices and a variable H-loop
at the active site (Fig. 2). Structural superposition of the unli-
ganded PDE5A1 over the complexes of PDE5A1-IBMX,
PDE5A1-sildenafil, and PDE5A1-icarisid II yielded r.m.s. devi-
ations of 0.29, 0.42, and 0.54 Å for the C atoms of comparable
residues (536–659, 684–787, and 810–860), respectively, sug-
gesting overall structural similarity. However, the H-loop (res-
idues 660–683 on the basis of the structural comparison with
seven other PDE families, which are slightly different from the
previous assignment of residues 661–676 (23)) adopts four
conformations anddifferent tertiary structures in the crystals of
the unliganded PDE5A1 and its complexes with IBMX, silde-
nafil, or icarisid II. In the unliganded PDE5A1 structure, the
H-loop contains a few turns, but the majority of the H-loop
TABLE 1
Statistics on diffraction data and structure refinement
Data collection PDE5A1 native PDE5A1-sildenafil PDE5A1-icarisid II
Space group P3121 P6222 P6122
Unit cell (a, b, and c, Å) 74.7, 74.7, 130.7 164.6, 164.6, 193.1 110.7, 110.7, 106.2
Resolution (Å) 1.85 2.3 1.8
Total measurements 363,960 1,121,219 412,999
Unique reflections 36,603 68,786 36,177
Completeness (%) 99.5 (100.0)a 99.9 (100.0) 99.9 (99.7)
Average I/ 20.8 (7.4)a 6.7 (4.8) 13.6 (4.3)
Rmerge 0.058 (0.49)a 0.117 (0.58) 0.061 (0.46)
Structure refinement
R-factor 0.221 0.210 0.206
R-free 0.236 (9.7%)b 0.246 (9.7%) 0.233 (9.7%)
Resolution (Å) 15–1.85 48–2.3 44–1.8
Reflections 34,996 66,315 35,094
r.m.s. deviation
Bond 0.0078 Å 0.0061 0.0073
Angle 1.25° 1.17° 1.31°
Average B-factor (Å2)
Protein 37.5 (2523)c 27.8 (7804) 27.9 (2650)
Inhibitor 29.4 (99) 25.9 (37)
Water 37.9 (148)c 28.8 (311) 32.8 (231)
Zinc 46.2 (1)c 44.9 (3) 36.6 (1)
Magnesium 33.4 (1)c 37.6 (3) 41.0 (1)
a The numbers in parentheses are for the highest resolution shell.
b The percentage of reflections omitted for calculation of R-free.
c The number of atoms in the crystallographic asymmetric unit.
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residues are in a coil conformation (Fig. 2). Binding of IBMX
converts the H-loop into two short -helices involving residues
664–667 and 672–676 (Fig. 2F) and shifts the C atoms of the
H-loop as much as 7 Å from those in the unliganded structure.
In the structure of the PDE5-sildenafil complex, the H-loop in
molecule A is converted to a turn and a 310 helix at residues
672–675, and the whole loopmigrates asmuch as 24Å to cover
the active site (Fig. 2). However, residues 668–676 of the
H-loop in molecules B and C are disordered. The most dra-
matic change in the H-loop occurs in the structure of PDE5A1-
icarisid II, in which the H-loop contains two -strands at resi-
dues 662–666 and 675–679 (Fig. 2F) and migrates as much as
35 Å from the position in the unliganded PDE5A1.
To verify that the conformational changes are not because of
an artifact of structure determination or crystal packing, elec-
tron density maps were calculated, and lattice interactions in
the various crystal forms were examined. The maps that were
calculated from the structure with omission of the H-loop
showed solid electron density for almost all residues of the
H-loops, thus confirming the true conformational variation in
the PDE5A1 structures. This is supported by the fact that the
B-factor for the H-loops is comparable with or slightly higher
than the overall average B-factor for the protein atoms as fol-
lows: 48 versus 38 Å2 for the unliganded PDE5A1, 61 versus 40
Å2 for PDE5A1-IBMX, 33 versus 33 Å2 for PDE5A1-icarisid II,
and 38 versus 27 Å2 for PDE5A1-sildenafil. In addition, the fol-
lowing facts suggest minor roles of the lattice contacts in the
conformational changes of the H-loop. First, the unliganded
PDE5A1 and its IBMX complex have the same space group and
the similar unit cell parameters (a  b  74.7, c  130.7 Å
versus a  b  74.5, c  130.1 Å) but different H-loop confor-
mations. Second, the PDE4 H-loop that was inserted into the
chimeric PDE5 structure is involved in the crystal lattice inter-
actions of PDE5 but retains its conformation found in PDE4
(22). Thus, the dramatic conformational changes of the H-loop
must be the consequence of binding of the specific inhibitors.
In addition to variation of the H-loop, minor conformational
differences are observed for another active site loop, the
M-loop (residues 788–811 on the basis of the structural com-
parison among seven PDE families, in comparison to the orig-
inal assignment of residues 787–812 (23)). Residues 793–807
of theM-loop are not traceable in the structures of the unligan-
ded or IBMX-bound PDE5A1. However, the well ordered
M-loops in the structures of PDE5A1 in complexwith sildenafil
or icarisid II contain an extra 310 helix and a 10-residue exten-
sion of -helix H14, in addition to the correspondence of a 310
helix to the N-terminal portion of H15 in the unliganded
PDE5A1 (Fig. 2F).
PDE5 shows an apparently unique feature distinct from
other PDE families, although the overall topological folding of
PDE5A is similar to those of PDE1B (22), PDE2A (32), PDE3B
(33), PDE4B and PDE4D (22–24, 34–38), PDE7A (25), and
PDE9A (39). The core catalytic domains of PDE1–4, -7, and -9
(residues 115–411 in PDE4D2), including the H-loop that is
composed of two short-helices (H8 andH9, residues 209–215
and 218–222 in PDE4D2l; see Fig. 2F) have a uniform confor-
mation and are superimposable on one another. In contrast, the
H-loop of PDE5A1 presents at least four different conforma-
tions, and none of these is comparable with any of the corre-
sponding H-loops in other PDE families. The closest compara-
ble conformation is the H-loop in the PDE5A1-IBMX
structure, which also contains two short -helices. However,
these twohelices have asmuch as 7Åpositional difference from
those in PDE4D2 (23) and are in a different three-dimensional
arrangement. In addition, the -strand component of the
H-loop in the PDE5A1-icarisid II complex is unique among
active sites of known PDE structures. Therefore, the active site
of PDE5 appears to belong to a special category of the PDE
superfamily.
Conformation Variation of Sildenafil—Sildenafil binds to each
active site of three PDE5A1 catalytic domains in the crystallo-
graphic asymmetric unit with similar conformation and occu-
pancy, as shownby thecomparableB-factor and thecleanelectron
density in theomittedmap (Fig. 3).Thebindingof sildenafil causes
a dramatic conformational change of the H-loop and a move-
ment as much as 24 Å from that in the unliganded PDE5 struc-
ture. A direct consequence of the H-loop movement is the
transformation of the open PDE5A1 active site to a closed
pocket. Sildenafil is partially buried in the pocket. Solvent-ac-
cessible surface of sildenafil after binding to PDE5A1 is reduced
to 9.4% of the total surface area. Sildenafil borders the metal-
binding pocket but does not directly interact with the metal
ions. The pyrazolopyrimidinone group (R1 in Fig. 1 andTable 2)
of sildenafil stacks against Phe820 of PDE5A1 and also contacts
residues Tyr612, Leu765, Ala767, and Gln817. The O1 and N4
atoms of pyrazolopyrimidinone form two hydrogen bonds with
N2 and O1 of Gln817, respectively. The ethoxyphenyl group
(R2, Fig. 1) interacts via van derWaals forceswithVal782, Ala783,
Phe786, Leu804, Ile813, Gln817, andPhe820. Themethylpiperazine
group (R3, Fig. 1) contacts Asn662, Ser663, Tyr664, Ile665, Leu804,
and Phe820. The oxygen atoms of the sulfone group interact
mainly with Phe820.
Our PDE5A1-sildenafil structure is similar in many respects
to those reported earlier (20–22), as shown by the r.m.s. devia-
tions of 0.59 and 0.40 Å for superposition of the backbone
atoms of the comparable residues (without 661–677) of our
PDE5A1-sildenafil over the two previous structures. However,
two significant differences are observed among the three
PDE5A-sildenafil structures. First, the H-loop in our structure
has definite electron density and different conformation from
those in the previously published structures in which the
H-loop is either disordered (missing residues 665–675) (20) or
FIGURE 2. Structures of PDE5 and its inhibitor complexes. A, ribbon diagram. The cyan ribbons are the common structures of the catalytic domains of
unliganded PDE5A1 and its complexes. The different conformations of the H-loop in the four structures are shown in purple for the unliganded PDE5A1,
blue for the IBMX complex, gold for the sildenafil complex, and green for the icarisid II complex. Zinc is colored red, and magnesium is purple. B–E, surface
presentation for the catalytic domain of the unliganded PDE5A1 (B) and its complexes with IBMX (C), sildenafil (D), or icarisid II (E). The middle red pocket
is the active site. The inhibitors are shown as color balls: blue for IBMX, gold for sildenafil, and green for icarisid II. Icarisid II is almost completely buried,
and the orientation of the domain is adjusted to show the icarisid II binding. F, the alignment of the secondary structures with the amino acid sequence
around the regions of the H- and M-loops that are shown in blue letters. The gold ribbon, green arrow, and cyan tube represent 310 helix, -strand, and
-helix, respectively. The dots represent disordered regions in the unliganded and IBMX-bound PDE5.
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FIGURE 3. Sildenafil binding. A, electron density for sildenafil bound to PDE5A1. The Fo  Fc map was calculated from the structure omitting sildenafil and
contoured at 3. B, stereoview of interactions of sildenafil (gold stick-balls) with the active site residues (salmon sticks). The dotted lines represent hydrogen
bonds. C, superposition of sildenafils from the PDE5A1-sildenafil structures of Zhang et al. (22) (gold), Sung et al. (20) (cyan), and ours (green).
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takes the PDE4 conformation because of chimeric replacement
of PDE5 residues 658–681with those of PDE4 (22). Second, the
conformations and the interactions of sildenafil in the three
PDE5A-sildenafil structures are significantly different.
Although the ethoxyphenyl and pyrazolopyrimidinone groups
of sildenafil in the three PDE5A structures are superimposable
and interact with the same residues of PDE5A, the meth-
ylpiperazine shows different orientations (Fig. 3). The meth-
ylpiperazinemoiety in our PDE5A1-sildenafil structure folds to
interact with the pyrazolopyrimidinone, in contrast to the con-
formation reported by Sung et al. (20) where the methylpipera-
zine extends in a different direction. The orientation of the
methylpiperazine in the structure of Zhang et al. (22) is more
similar to ours, but the ring is tilted by40° (Fig. 3). In addition,
the contacts between the methylpiperazine and the PDE5 resi-
dues in the structure reported hereinmarkedly differ fromboth
previously published structures. In the structure reported
herein, the methylpiperazine interacts with Asn662, Ser663,
Tyr664, and Ile665 in theH-loop (Table 2).However, there are no
contacts between the methylpiperazine and the H-loop in the
structure of Zhang et al. (22), and the methylpiperazine con-
tacts Tyr664,Met816, Gly819, and Phe820 in the structure by Sung
et al. (20).
To exclude possible false results from the structure determi-
nation, we compared this study and previously published struc-
tures of the PDE5A-sildenafil complex. The 2Fo  Fc and Fo 
Fc maps that are calculated from the PDE5A catalytic domains
with omission of sildenafil show reasonable electron density for
all three sildenafils, suggesting their true bound conformations
in the crystal states. Thus, the basis for the conformational dif-
ferences of sildenafil needs to be explored. The 40° tilt of the
methylpiperazine ring in the Zhang structure may be the con-
sequence of the chimeric replacement of the PDE5H-loop (res-
idues 658–681) with the equivalent amino acids of PDE4 (22),
which takes the conformation of PDE4 in that structure. For the
structure of PDE5A-sildenafil of Sung et al. (20), the electron
density maps show that Cys677 probably forms an intermolec-
ular disulfide bondwithCys677 fromaneighboringmonomer in
the PDE5A crystal. Thus, the catalytic domain of PDE5A in the
structure of Sung et al. (20) forms a dimer, in contrast to a
monomeric form in the PDE5A-sildenafil structures of ours
and Zhang et al. (22). The fact that the specific activity of the
catalytic domain of Sung et al. (20) is only about one-thou-
sandth of that reported for monomeric PDE5A (see Ref. 40 and
this study) suggests that the dimer may be either a less active
form of PDE5 or a crystallization artifact.
Binding of Icarisid II to PDE5—Icarisid II is a glycoside deriv-
ative of flavonoids from the plantEpimediumwanshanense that
has been used as an herbal medicine for improvement of erec-
tile dysfunction in China for more than a thousand years (41–
44). Icarisid II inhibits PDE5A1 with an IC50 of 2 M and shows
at least 10-fold selectivity against other PDEs. It binds to the
active site of PDE5A1, as shown by the electron density that is
calculated from the PDE5A1 structure before icarisid II was
built into the structure (Fig. 4). The binding of icarisid II causes
formation of two -strands in the H-loop and as much as 35 Å
movement of the H-loop to completely close the active site
(Figs. 2E and 4). The solvent-accessible area of icarisid II after
binding to the active site of PDE5A1 is reduced to 0.05% of the
unbound form.
Five hydrogen bonds are formed between icarisid II and
PDE5A1. The oxychromone (R2, Fig. 1 andTable 2) of icarisid II
stacks against Phe820, and its oxygen atoms O4 and O10 form
three hydrogen bonds with the backbone nitrogen of Ile665, the
side chain oxygen of Ser668, and a water molecule. It also inter-
acts with residues Tyr664, Leu725, Leu804, and Met816 (Fig. 4).
The methoxyphenyl group (R1, Fig. 1) forms a hydrogen bond
with the backbone nitrogen of Ile768 and makes van der Waals
contacts with Ala767, Ile768, Gln775, Ala779, Gln817, and Phe820
(Table 2). The pentenyl group (atoms C17-C21, Fig. 1) forms
hydrophobic contacts with Val782, Phe786, Leu804, Met816, and
Gln817. The rhamnose group (R3, Fig. 1) forms three hydrogen
TABLE 2
Interactions of sildenafil and icarisid II with PDE5A
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FIGURE 4. Icarisid II binding. A, electron density for icarisid II bound to PDE5A1. The Fo  Fc map was calculated from the structure with omission of icarisid II
and contoured at 3.0. B, stereoview of interaction of icarisid II (gold sticks) with the PDE5A1 residues (salmon sticks) at the active site of PDE5A1. The dotted lines
represent hydrogen bonds. C, superposition of icarisid II (gold sticks) and sildenafil (purple ball-sticks). Residues from PDE5A-sildenafil are shown in blue, and
residues from the icarisid II complex are in green. The side chain of Gln817 has the different conformations in the two structures.
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bonds with N2 of His613, O2 of Asp764, and a water molecule,
in addition to interactions with residues Tyr612, His613, Asn661,
Ser663, Leu725, Asp764, Leu765, and Phe820 (Table 2). A few
atoms of rhamnose are located at distance suitable for van der
Waals contact with both metal ions and directly interact with
some of the metal-binding residues such as Asp764.
Although icarisid II and sildenafil occupy the same active
site, the detailed interactions of the inhibitors are significantly
different (Fig. 4). Sildenafil forms two hydrogen bonds with
Gln817 and stacks against Phe820. However, Gln817 shows about
90° rotation of its side chain (Fig. 4) and forms no hydrogen
bond with icarisid II. The hydrogen bond between the side
chain atoms of O1 of Gln775 and N2 of Gln817 in the unligan-
ded PDE5 and its complex with IBMX and sildenafil vanishes in
the PDE5-icarisid II structure, and the two atoms separate by
4.3 Å. The conformational change of the side chain Gln817 in
the icarisid II structure appears to be a consequence of its unfa-
vorable proximity to the hydrophobic pentenyl and phenyl
groups. In addition, the position of oxychromone of icarisid II,
which stacks against Phe820, is significantly different from the
pyrazolopyrimidinone of sildenafil. In consideration of the
1000-fold difference in binding affinity between sildenafil and
icarisid II, the structural data suggest that the hydrogen bond
with Gln817 and the stacking against Phe820 are two essential
components for high affinity binding of inhibitors. This result is
consistent with an established role of Gln817 in providing for
high potency of sildenafil, vardenfil, and tadalafil (45).
A Potential Role of the H-loop in Substrate/Inhibitor
Recognition—To understand the biochemical basis of multiple
conformations of the H-loop, two deletion mutants were cre-
ated in the isolated catalytic domain of PDE5A1. The PDE5A1
mutant with deletion of residues 663–678 and insertion of four
glycines (to minimize perturbation of the structure) showed
about 10- and 2-fold lower affinity for cGMP and the inhibitors,
respectively (Table 3 and Fig. 5). The mutant protein in which
residues 661–681 had been deleted and four glycines had been
inserted had a 150-fold weakerKm value for cGMP and 30–80-
fold less potent IC50 value for the inhibitors (Table 3). However,
both mutants had kcat values comparable with that of the wild
type PDE5A1 catalytic domain. These data imply that the
H-loop has a very important role for interaction of PDE5A1
with the cGMP substrate but appears to be less critical in inter-
action with icarisid II or sildenafil than with cGMP. This is
consistent with an earlier report that a sildenafil homolog
UK-122764 that lacks methylpiperazine and thus interac-
tions with the H-loop shows only a 5-fold lower potency than
sildenafil (46).
To pinpoint residues that impact cGMP binding affinity, sin-
gle mutations were performed on selected H-loop residues
(Val660, Asn661, Asn662, Tyr664, His678, and Ser679) in full-length
human PDE5A1, in addition to Gly659, an invariant amino acid
among all class I PDEs. Mutation of Gly659 to alanine (G659A)
caused a 17-fold loss of kcat and 24-fold weaker affinity for
cGMP (Table 4). The N662A mutant exhibited a modest loss
(5-fold) in affinity for cGMP and a 9-fold decrease in kcat.Muta-
tion ofH678Adid not appreciably impact the binding affinity of
substrate or catalytic activity. The remaining mutations
(V660Q, N661A, Y664A, and S679A) did not significantly
change kcat but caused a 24–28-fold loss in affinity for cGMP
(Table 4). To verify the overall structural integrity of the full-
length PDE5A1 constructs, cGMP binding to the allosteric
cGMP sites in the regulatory domain of each mutant was
assessed.Wild type andmutant PDE5A1proteins bound cGMP
with comparable affinity (Kd in the range of 190–230 nM) and
stoichiometry (0.50–0.55 mol of cGMP per PDE5A1 mono-
mer), in good agreement with values reported previously for
FIGURE 5. Inhibition of the isolated PDE5 catalytic domain of wild type and H-loop deletion mutants by IBMX, icarisid II, and sildenafil.
TABLE 3
Kinetic properties of PDE5A1-(535– 860) isolated catalytic domain and its mutants
KmcGMP kcatcGMP (kcat/Km)cGMP IBMX Icarisid II Sildenafil
M s1 s1 M1 IC50 M IC50 M IC50 nM
Wild type 5.1  1.3 1.3  0.3 0.27  0.08 2.1  0.5 1.7  0.4 2.4  0.3
(663–678)a 54  6 3.8  0.5 0.07  0.013 5.3  1.1 2.5  0.2 5.9  1.5
(661–681)a 750  210 2.3  0.6 0.0031  0.0002 95  6 55  13 188  29
a Four glycines were inserted as a linker. Each of the experiments was repeated three times.
TABLE 4
Kinetic properties of full-length wild type PDE5A1 and PDE5A1
mutant proteins
KmcGMP (kcat/Km)cGMP (kcat/Km)cGMP
M s1 s1 M1
Wild type 2.95  0.81 1.67  0.31 0.57
G659A 71.20  1.22 0.112  0.00013 0.0016
V660Q 82.06  8.46 2.53  0.71 0.031
N661A 68.06  4.32 0.86  0.04 0.013
N662A 15.15  1.92 0.18  0.10 0.012
Y664A 80.36  8.76 1.51  0.35 0.019
H678A 3.87  0.10 0.53  0.06 0.14
S679A 70.28  5.45 1.83  0.37 0.026
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recombinant bovine PDE5 (40). These data indicate that overall
structures of the mutant proteins are preserved and that differ-
ences in kinetic parameters for the mutants are not because of
nonspecific conformational effects.
Properties of the G659Amutant can be explained on basis of
the PDE structures. Gly659 is invariant in all class I PDE families,
immediately precedes the H-loop, and is likely to provide crit-
ical flexibility at this juncture in the protein structures. Gly659
has backbone conformational angles of   76–105°,  
3–22°, and 	  180° in the structures of PDE5A1-sildenafil,
PDE5A1-icarisid II, and other PDE families, and  104–109°,
  139–141°, and 	  180° in the unliganded and IBMX-
bound PDE5A1. All of these / conformational angles are
allowed only for glycine but are not allowed for all other amino
acids. Thus, mutation of Gly659 to any other amino acid would
impose restrictions on the conformation of the H-loop or even
distort the conformation of the active site, thus profoundly
impairing the catalytic activity of the mutant PDE5.
The kinetic data indicate that the majority of the H-loop
mutants affect Km values for cGMP but have much less effect
in catalytic turnover rate (Table 4). Although no interactions
between the H-loop and the low affinity product GMP were
observed in the chimeric PDE5-GMP structure (22), it is
plausible that the H-loopmay contact cGMP in a pattern like
that of sildenafil or icarisid II. Because hydrolysis of the
phosphodiester bond of cGMP occurs in the metal-binding
subpocket, the distal position of the H-loop from the metal
site in the structure would be more consistent with its role in
substrate binding rather than hydrolysis. This would imply a
dynamic interplay between the H-loop and substrate, in
which binding of cGMP and the H-loop conformation would
mutually regulate one another. Further structural studies
will be required to completely define the mechanism
involved in the H-loop modulation of substrate affinity and
inhibitor binding.
DISCUSSION
Extensive studies on the crystal structures of PDEs have
shown that the PDE families have similar overall three-dimen-
sional structures for their isolated catalytic domains and active
sites (20–25, 32–39). However, information on the conforma-
tion of the PDE5 active site and on sildenafil binding is incom-
plete because early studies showed a disordered or artificially
replaced H-loop at the active site (20–22). This study, in com-
bination with our PDE5A1-IBMX structure (23), reveals that
the H-loop of PDE5 can adopt four clearly defined conforma-
tions. These different conformations of the H-loop of PDE5
may be the result of direct contacts between the H-loop and
inhibitors, such as those in the structures of PDE5A1 in com-
plex with sildenafil or icarisid II. Alternatively, the H-loop
changes may be imposed by more distant effects of conforma-
tional changes following inhibitor occupation of the binding
pocket, as implicated by no direct contacts between the H-loop
and IBMX. Finally, a combination of both direct and indirect
interactions may contribute to the H-loop changes. Because all
other PDEs appear to have a similar conformation of theH-loop
that is not comparable with any of the conformations of the
PDE5 H-loop, the PDE5 active site apparently has a unique
structural characteristic. The mutual communication between
inhibitor binding and conformational changes of the PDE5 cat-
alytic pocket may thus be a valuable consideration for design of
new inhibitors with unique selectivity against PDE5.
It is common that an inhibitor slightly adjusts its conforma-
tion to provide an optimal fit in the binding pocket of a protein.
However, the conformational variation of sildenafil in the dif-
ferent crystal forms, as seen in the significantly different con-
formations of the methylpiperazine group, is unusual. Because
inhibitors are commonly designed tomimic contacts employed
by the substrate, the dramatic effect of the H-loop mutations
on affinity for cGMP and the flexibility of sildenafil provide
potentially important direction in development of new PDE5
inhibitors.
Side effects such as visual disturbances in patients who ingest
PDE5 inhibitors (19) dictate a need for detailed study of the
molecular basis for the action of these drugs and development
of new potential inhibitors. Derivatives of flavonoids such as
icarasid II may be such a new category of PDE5 inhibitors. Fla-
vonoids inhibit PDEs with affinity at the micromolar level and
slight selectivity (47, 48), and are widely used as dietary supple-
ments that have reached a multiple billion dollar business (49–
51). In the present report, the structure of PDE5A1-icarisid II
shows how this natural dietary compound interacts with PDE5
and thus provides a valuable guideline for development of a new
category of PDE5 inhibitors.
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